# Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus

> **NCT06691152** · PHASE1 · RECRUITING · sponsor: **The Children's Hospital of Zhejiang University School of Medicine** · enrollment: 18 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** CD19 Universal CAR-T cells

## Key facts

- **NCT ID:** NCT06691152
- **Lead sponsor:** The Children's Hospital of Zhejiang University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06691152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06691152, "Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06691152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*